Free Trial

Coloplast A/S Q2 2024 Earnings Report

Coloplast A/S logo
$11.09 +0.21 (+1.93%)
(As of 12/20/2024 05:55 PM ET)

Coloplast A/S EPS Results

Actual EPS
$0.08
Consensus EPS
$0.08
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Coloplast A/S Revenue Results

Actual Revenue
$959.05 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Coloplast A/S Announcement Details

Quarter
Q2 2024
Time
N/A

Conference Call Resources

⭕ [URGENT] Buy Alert just triggered (Ad)

My absolute favorite stock just hit a critical "buy now" trigger price.

Click here for the ticker >>>

Coloplast A/S Earnings Headlines

Coloplast A/S (CLPBF) Q4 2024 Earnings Call Transcript
⭕ [URGENT] Buy Alert just triggered
My absolute favorite stock just hit a critical "buy now" trigger price.
Coloplast A/S - Financial Calendar 2024-25
See More Coloplast A/S Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Coloplast A/S? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Coloplast A/S and other key companies, straight to your email.

About Coloplast A/S

Coloplast A/S (OTCMKTS:CLPBY) engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. The company was founded in 1954 and is headquartered in Humlebæk, Denmark.

View Coloplast A/S Profile

More Earnings Resources from MarketBeat

Upcoming Earnings